




## Olaparib

Revised: December 3, 2018.

CASRN: 763113-22-0



## Drug Levels and Effects

### Summary of Use during Lactation

No information is available on the clinical use of olaparib during breastfeeding. Because olaparib is 82% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during olaparib therapy and for one month after the last dose.

### Drug Levels

*Maternal Levels.* Relevant published information was not found as of the revision date.

*Infant Levels.* Relevant published information was not found as of the revision date.

## Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

## Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

## Substance Identification

### Substance Name

Olaparib

### CAS Registry Number

763113-22-0

### Drug Class

Breast Feeding

Lactation

Antineoplastic Agents

Enzyme Inhibitors

Signal Transduction Inhibitors

PARP inhibitors